Cannell & Co’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-281,983
| Closed | -$293K | – | 257 |
|
|
2019
Q1 | $293K | Sell |
281,983
-21,088
| -7% | -$17.2K | 0.01% | 218 |
|
|
2018
Q4 | $226K | Hold |
303,071
| – | – | 0.01% | 222 |
|
|
2018
Q3 | $643K | Hold |
303,071
| – | – | 0.02% | 197 |
|
|
2018
Q2 | $700K | Sell |
303,071
-900
| -0.3% | -$2.62K | 0.03% | 187 |
|
|
2018
Q1 | $967K | Hold |
303,971
| – | – | 0.04% | 167 |
|
|
2017
Q4 | $1.25M | Hold |
303,971
| – | – | 0.04% | 156 |
|
|
2017
Q3 | $1.37M | Sell |
303,971
-103,770
| -25% | -$420K | 0.05% | 156 |
|
|
2017
Q2 | $1.36M | Buy |
407,741
+76,445
| +23% | +$317K | 0.05% | 153 |
|
|
2017
Q1 | $3.05M | Buy |
331,296
+79,068
| +31% | +$694K | 0.11% | 129 |
|
|
2016
Q4 | $1.95M | Sell |
252,228
-37,300
| -13% | -$343K | 0.07% | 135 |
|
|
2016
Q3 | $3.31M | Hold |
289,528
| – | – | 0.12% | 125 |
|
|
2016
Q2 | $3.56M | Buy |
289,528
+79,125
| +38% | +$960K | 0.13% | 120 |
|
|
2016
Q1 | $2.13M | Hold |
210,403
| – | – | 0.08% | 138 |
|
|
2015
Q4 | $4.74M | Hold |
210,403
| – | – | 0.15% | 102 |
|
|
2015
Q3 | $3.49M | Buy |
210,403
+27,400
| +15% | +$549K | 0.11% | 118 |
|
|
2015
Q2 | $4.12M | Buy |
183,003
+136,349
| +292% | +$3.36M | 0.12% | 119 |
|
|
2015
Q1 | $1.2M | Buy |
+46,654
| New | +$1.18M | 0.03% | 166 |
|
Cannell & Co's OMED Position: Q2 2019 in Review
Cannell & Co sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 281,983 shares — an estimated $293K sold.
Cannell & Co first reported a position in OMED in Q1 2015 and held it in 17 quarters. The position peaked at $4.74M in Q4 2015. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- Cannell & Co reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- Cannell & Co sold 281,983 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $293K.
- Cannell & Co first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2015 and held it in 17 quarters.
- Cannell & Co's OncoMed Pharmaceuticals, Inc. position peaked at $4.74M in Q4 2015.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on Cannell & Co's 13F filing for Q2 2019, filed 12 Aug 2019.